Survival Benefit Persists With Ribociclib in HR+/HER2- Advanced Breast Cancer
Cancer Therapy Advisor,
Adding ribociclib to endocrine therapy provided a persistent benefit in overall survival (OS) for patients with hormone…
Adding ribociclib to endocrine therapy provided a persistent benefit in overall survival (OS) for patients with hormone…
Key clinical point: With an extended median follow-up of 53.5 months, ribociclib+endocrine therapy (ET) continued to prolong…
The University of Texas MD Anderson Cancer Centers Research Highlights provides a glimpse into recently published studies in…
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in…